Immunohistochemical study of the neural development transcription factors (TTF1, ASCL1 and BRN2) in neuroendocrine prostate tumours. / Estudio inmunohistoquímico de los factores de trancripción de desarrollo neural (TTF1, ASCL1 y BRN2) en los tumores neuroendocrinos de próstata.

OBJECTIVE: Prostatic small-cell neuroendocrine carcinoma is an uncommon malignancy that constitutes 0.5-1% of all prostate malignancies. The median cancer-specific survival of patients with prostatic small-cell neuroendocrine carcinoma is 19 months, and 60.5% of the patients have metastatic disease. Neural development transcription factors are molecules involved in the organogenesis of the central nervous system and of neuroendocrine precursors of various tissues, including the suprarenal gland, thyroid glands, lungs and prostate. MATERIAL AND METHODS: We present 3 cases of this uncommon condition, applying the new World Health Organisation criteria. We conducted studies through haematoxylin and eosin staining and analysed the expression of the neural development transcription factors achaete-scute homolog like 1, thyroid transcription factor 1 and the class III/IV POU transcription factors, as a new research line in the carcinogenesis of prostatic neuroendocrine tumours. RESULTS: In case 1, there was no TTF1 immunoexpression. Cases 2 and 3 had positive immunostaining for ASCL1, and Case 1 had negative immunostaining. BRN2 immunostaining was negative in case 1 and positive in cases 2 and 3. CONCLUSION: The World Health Organisation does not recognise any molecular or genetic marker with prognostic value. ASCL-1 is related to the NOTCH and WNT signalling pathways. ASCL-1, TTF1 and BRN2 could be used for early diagnosis and as prognostic factors and therapeutic targets.

Hiperplasia difusa idiopática de células neuroendocrinas de pulmón (DIPNECH): una entidad preneoplásica, infradiagnosticada y poco conocida / Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): a little-known, underdiagnosed preneoplastic lesion

La hiperplasia difusa idiopática de células neuroendocrinas de pulmón aparece recogida en la clasificación de la OMS de tumores torácicos desde el año 1999 como una lesión epitelial preinvasiva caracterizada por una proliferación generalizada de células dispersas y aisladas, nódulos pequeños (cuerpos neuroendocrinos) o proliferaciones lineales de células neuroendocrinas pulmonares, confinadas al epitelio bronquial o bronquiolar, e incluye proliferaciones locales extraluminales (tumorlets o carcinoides). En la presente revisión se actualizan los criterios morfológicos cuantitativos establecidos recientemente y se consideran nuevos aspectos cualitativos que pueden contribuir a una mejor caracterización de la entidad (AU)

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia appears in the WHO classification of thoracic tumours since 1999 as a preinvasive epithelial lesion characterized by a proliferation of scattered and isolated cells, small nodules (neuroendocrine bodies) or linear pulmonary neuroendocrine cell proliferations, confined to the bronchial or bronchiolar epithelium, including extraluminal local proliferations (tumorlets or carcinoids). In this review we update the recently established quantitative morphological criteria and new qualitative aspects are considered to contribute to a better characterization of the entity (AU)

Novel method for isolating human melanoblasts from keratinocyte culture.

The characterization of melanoblasts is important for understanding their in vivo development, melanoma formation, and pigment-related disorders. However, no methods have been reported for the isolation of melanoblasts from human skin. Using a 'calcium-pulse' technique, involving the differentiation of human keratinocytes with high calcium and the subsequent spontaneous separation of the epidermal sheets, we effectively isolated human melanoblasts (keratinocyte-adapted melanoblasts, KaMBs) from keratinocyte culture. The KaMBs expressed early melanogenesis-related genes, including BRN2, which is a known melanoblast marker. Moreover, the KaMBs displayed much higher proliferative and growth capacities than the primary melanocytes. Considering that keratinocytes might provide an in vivo-like environment for KaMBs during isolation and in vitro culture, the 'calcium-pulse' technique offers an unprecedented, easy, and efficient method for the isolation of human melanoblasts, retaining the original characteristics of these cells.

SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells.

Nestin is an intermediate filament protein and a marker of neuroectodermal stem cells indicating multipotentiality and regenerative capability. In melanoma tissues, nestin re-expression was correlated with tumor progression. Activation of the nestin neural enhancer was shown to be dependent on the binding of class III POU transcription factors, with brain-2 (BRN2) suggested to play a key role. We found both nestin and BRN2 mRNA in almost all of 13 analyzed melanoma cell lines of different progression stages, but expression levels did not correlate. Nestin protein was detected in 11 of 13 and BRN2 protein in 7 of 13 melanoma cell lines independent of progression stage. Downregulation of BRN2 by small-interfering RNA did not alter nestin expression in melanoma cells. However, POU proteins, such as BRN2, commonly cooperate with transcription factors of the Sry-box (SOX) family by binding to a nearby DNA site necessary for their action. SOX9 and SOX10 have been shown to be expressed in melanocyte precursors, with SOX10 downregulated upon differentiation. We now demonstrate SOX9 and SOX10 protein expression in melanoma tissues and cell lines. Downregulation of SOX9 and of SOX10 markedly decreased nestin levels in melanoma cells in a cooperative manner. Thus, SOX9 and SOX10 but not BRN2 seem to be required for nestin expression in human melanoma.

Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas.

Histologic, molecular, and epidemiologic data suggest that cutaneous melanomas arise through diverse causal pathways, one of which appears mediated by chronic sunlight exposure, and another associated with a nevus-prone phenotype. To further explore etiologic heterogeneity, we compared expression of key melanoma-related proteins according to histologic characteristics of the tumors and epidemiologic risk factors among a sample of 129 patients newly diagnosed with melanoma. Tumor tissue was stained with antibodies to phospho-mitogen-activated protein kinase (P-MAPK), Brn-2, retinoblastoma protein (pRb), p53, and p16. Using logistic regression analysis, we estimated the odds ratio (OR) and 95% confidence interval (95% CI) of protein expression associated with factors of interest. Except for pRb, candidate protein expression was detected in fewer than half the melanomas examined (P-MAPK, 39%; Brn-2, 30%; p53, 24%; p16, 41%). Strong pRb expression was associated with the presence of >20 solar keratoses (OR 6.5, 95% CI: 1.7-25.1) and melanomas with marked to moderate solar elastosis. p53 expression was positively associated with skin that readily burned (OR 3.8, 95% CI: 0.8-19.0) and was inversely associated with >60 nevi (OR 0.3, 95% CI: 0.04-1.5). Melanomas expressing P-MAPK were more likely to have contiguous neval remnants (OR 2.7, 95% CI: 1.1-6.5). P-MAPK and Brn-2 immunopositive melanomas were >/=4-fold more likely to be of the superficial spreading subtype. Brn-2 and p16 immunopositive melanomas had a greater Breslow thickness than melanomas that did not express these proteins. Brn-2, pRb, and p16 proteins were consistently coexpressed. These findings support the hypothesis that molecular profiles of melanoma reflect their histologic and epidemiologic characteristics, offering further evidence of more than one melanoma causal pathway. Exactly how the expression of each protein relates to the causal pathways needs to be further explored.

Expression and antibody preparation of POU transcription factor qBrn-1.

The transcription factor Brn-1, which belongs to POU-domain family, has been shown to play critical roles in the development of the nervous system. A cDNA clone coding for a quail Brn-1 homologue, qBrn-1, was isolated. To investigate whether this gene plays a role in the development of the quail nervous system, an anti-N-terminal peptide antibody was prepared. The coding region for amino acids 1-79 (the N-terminal domain of qBrn-1) was subcloned into Trx fusion expression vector pET32c and introduced into the Escherichia coli Origami(DE3) cells for efficient expression. After purification, Trx-fused polypeptides, called Trx-qBrn-1N, were used to immunize the rabbits to prepare polyclonal antibodies against qBrn-1. The produced and purified antiserum showed specificity not only to the in vitro expressed qBrn-1, but also to the natural qBrn-1 in tissues. Immunolabeling on sections by the anti-qBrn-1 serum showed that qBrn-1 was specifically expressed in the developing spinal cord and kidney. This suggests that qBrn-1 may play some roles in the development of avian nervous system and kidney, and the preparation of anti-qBrn-1 polyclonal antibody will facilitate further detection of, and functional study on, qBrn-1 both in vivo and in vitro.